Though shares of Celldex Therapeutics Inc. plunged 26.2 percent on the news, President and CEO Anthony Marucci sees Pfizer Inc.'s decision to return rights to brain cancer vaccine CDX-110 (rindopepimut) as a positive event for his company. (BioWorld Today) Read More
